European Union Recommended NAION Warnings In June 2025, the European Medicines Agency (EMA) recommended updating the labeling for semaglutide to list NAION as a very rare side effect, affecting up to 1 in 10,000 users
It's a meaningful indicator that the platform has been reviewed against defined standards, though it doesn't guarantee clinical outcomes or predict future regulatory changes
Jeffrey cites recent findings in which nearly one in three people taking the medication will experience a nutritional deficiency within 12 months
With it, the ratio flips dramatically
I'm about at the end of my rope on that one because I'm hearing, actually, intelligent people perpetuate that myth, and it's getting tiresome
He subsequently received semaglutide up to 2 mg subcutaneously weekly without any further episodes of allodynia or dysesthesia